The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine
NCT ID: NCT05492643
Last Updated: 2022-10-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1000 participants
INTERVENTIONAL
2022-08-13
2023-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Group A: will enrol 500 participants who have received 2 doses of inactivated SARS-CoV-2 vaccine according to national immunization planning, whose last dose was given at least 6 months ago. They will be given one dose of the study vaccine (SYS6006) after enrolment.
Group B: will enrol 500 participants who have received 3 doses of inactivated SARS-CoV-2 vaccine according to national immunization planning, whose last dose was given at least 6 months ago. They will be given one dose of the study vaccine (SYS6006) after enrolment.
The study is devided into two stages, the first stage will enrol 200 participants with 100 in Group A and 100 in Group B. They will undergo laboratory examination, immunogenicity observation and safety observation. The first 30 participants in each group will take extra cellular immune testing; the second stage will enrol the remaining 800 participants for safety observation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More
NCT05439824
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.
NCT05354089
Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above
NCT05664932
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
NCT05960097
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.
NCT05354063
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Immunogenicity Subgroup: the first 100 participants enrolled in group A will be assigned to Group A1; the first 100 participants enrolled in group B will be assigned to Group B1. Blood samples will be taken from Group A1 and Group B1 participants (200 in total) for humoral immunity testing and laboratory examination.
Laboratory examination include blood routine examination, urine routine test, blood biochemistry, coagulation, thyroid function, cardiac enzymes and troponin.
Humoral immunity testing include serum SARS-CoV-2 neutralizing antibody detection as measured by live virus and pseudovirus assay, S1 protein specific IgG binding antibody detection as measured by ELISA.
Cellular immunity Subgroup: the first 30 participants enrolled in Group A1 and Group B1 will take extra blood samples for specific cellular immune response (60 in total) as measured by ELISpot.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A：2 doses of inactivated SARS-CoV-2 vaccine
Group A: will enrol 500 participants who have received 2 doses of inactivated SARS-CoV-2 vaccine according to national immunization planning, whose last dose was given at least 6 months ago. They will be given one dose of the study vaccine (SYS6006) after enrolment.
one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
all the 1000 participants enrolled will be given one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
Cellular Immunity
the first 30 participants enrolled in each group will take extra blood samples for specific cellular immune response as measured by ELISpot.
Humoral Immunity
the first 100 participants enrolled in each group will take extra blood samples for humoral immunity testing and laboratory examination.
Safety
all the 500 participants enrolled will undergo safety observation
Group B：3 doses of inactivated SARS-CoV-2 vaccine
Group B: will enrol 500 participants who have received 3 doses of inactivated SARS-CoV-2 vaccine according to national immunization planning, whose last dose was given at least 6 months ago. They will be given one dose of the study vaccine (SYS6006) after enrolment.
one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
all the 1000 participants enrolled will be given one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
Cellular Immunity
the first 30 participants enrolled in each group will take extra blood samples for specific cellular immune response as measured by ELISpot.
Humoral Immunity
the first 100 participants enrolled in each group will take extra blood samples for humoral immunity testing and laboratory examination.
Safety
all the 500 participants enrolled will undergo safety observation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
all the 1000 participants enrolled will be given one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
Cellular Immunity
the first 30 participants enrolled in each group will take extra blood samples for specific cellular immune response as measured by ELISpot.
Humoral Immunity
the first 100 participants enrolled in each group will take extra blood samples for humoral immunity testing and laboratory examination.
Safety
all the 500 participants enrolled will undergo safety observation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Vaccinated with 2 or 3 doses of marketed inactivated SARS-CoV-2 vaccine according to national immunization planning, whose last dose was given at least 6 months ago;
3. Willing and able to comply with study requirements, and other study procedures within 6 months after vaccination;
4. Female participants or partners of male participants of childbearing potential: from the first day of last menstruation cycle to the day of enrolment, must had no sexual behavior with a male or had effective contraceptive methods without failure; voluntarily agree to maintain abstinent or use effective contraception with their partners until 6 months after vaccination;
5. Based on medical history enquiry, physical examination, and blood routine examination, the investigator judges the participants as in a healthy status; Participants with mild underlying disease (for example chonic diseases like diabetes/hypertension/hyperlipemia, etc.) must be in a stable state without exacerbation (no admission to hospital or no major adjustment to treatment regimen, etc.) for at least 3 months prior to enrollment in this study.
6. Understand the contents of the ICF and voluntarily sign it.
Exclusion Criteria
2.History of Severe Acute Respiratory Syndrome (SARS), or SARS-CoV-2 infections.
3.History of allergy to any component of the study vaccine or history of severe allergic reaction to the vaccine or drug (including but not limited to anaphylaxis, allergic laryngeal oedema, anaphylactic purpura, thrombocytopenic purpura, or localized allergic necrosis (Arthus reaction)).
4.Positive SARS-CoV-2 RT-PCR results. 5.Axillary temperature ≥37.3°C at enrolment or 24 hours prior to vaccination. 6.Had a history of Human Immuno-deficiency Virus(HIV) infection or positive HIV test result before enrolment.
7.A history or family history of convulsions, epilepsy, encephalopathy and psychosis.
8.Malignant tumors in the active phase, malignant tumors not receiving adequate treatment, malignant tumors at potential risk of recurrence during the study period.
9.With severe or un-controllable cardiovascular disease, thrombotic disease, neurological disease, blood and lymphatic system disease, liver and kidney disease, respiratory system disease, metabolic, skeletal muscular disease and autoimmune disease.
10.Congenital or functional splenic deficiency, complete or partial splenectomy for any reason.
11.Prolonged (defined as more than 14 days) use of immunosuppressive or other immunomodulatory drugs (e.g., corticosteroids, ≥20 mg/d prednisone or equivalent; however, inhaled and topical steroids are permitted) within 6 months prior to the vaccine.
12.Any other inactivated vaccines given within 7 days prior to the study vaccination, or live-attenuated vaccines within 14 days prior to the study vaccination.
13.Have received immunoglobulin or other blood products within 3 months prior to enrollment or plan to receive them during the study period.
14.Blood donation or blood loss ≥ 450 mL within 1 month prior to enrolment, or planned donation during the study period.
15.Is currently in or intent to participate in another clinical study at any time during the conduct of this study.
16.For Women of Childbearing Potential (WOCBP): with a positive urine pregnancy test before vaccination; pregnant or lactating; or have a plan to become pregnant within 6 months after enrolment. For male participants whose partner is WOCBP: whose partner has a plan to become pregnant within 6 months after her partner's enrolment.
17.With a history of intramuscular injection contraindication. For example: diagnosed thrombocytopenia, and coagulation disorder or received anticoagulation therapy.
18.Participants deemed unsuitable for participation in this study based on the investigator's assessment.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhongnan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xinghuan Wang
Role: PRINCIPAL_INVESTIGATOR
Wuhan University
Jianying Huang
Role: PRINCIPAL_INVESTIGATOR
Wuhan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SYS6006-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.